Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-05-19
2009-11-17
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S317000
Reexamination Certificate
active
07619005
ABSTRACT:
Cognitive impairments in humans with multiple sclerosis are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.
REFERENCES:
patent: 2828343 (1958-03-01), Tindall
patent: 3728445 (1973-04-01), Bardani
patent: 3996381 (1976-12-01), Florvall et al.
patent: 4034113 (1977-07-01), Shulgin
patent: 4105695 (1978-08-01), Partyka et al.
patent: 4479932 (1984-10-01), Bodor
patent: 4598094 (1986-07-01), Wurtman et al.
patent: 4636494 (1987-01-01), Growdon et al.
patent: 4647591 (1987-03-01), Cherkin et al.
patent: 5019594 (1991-05-01), Wurtman et al.
patent: 5075338 (1991-12-01), Knoll et al.
patent: 5096712 (1992-03-01), Wurtman
patent: 5151449 (1992-09-01), Milgram
patent: 5220068 (1993-06-01), Knoll et al.
patent: 5225446 (1993-07-01), Milgram
patent: 5422355 (1995-06-01), White et al.
patent: 5684018 (1997-11-01), Alexander
patent: 5914129 (1999-06-01), Mauskop
patent: 6104956 (2000-08-01), Naritoku et al.
patent: 6204245 (2001-03-01), Siegel et al.
patent: 6228875 (2001-05-01), Tsai et al.
patent: 6251938 (2001-06-01), Chorev et al.
patent: 6284760 (2001-09-01), Marston et al.
patent: 6451806 (2002-09-01), Farrar
patent: 6492427 (2002-12-01), Shankar et al.
patent: 6635675 (2003-10-01), Kranzler et al.
patent: 6699495 (2004-03-01), Blume et al.
patent: 6828351 (2004-12-01), Epstein et al.
patent: 7244769 (2007-07-01), Epstein et al.
patent: 2002/0066457 (2002-06-01), Landfield et al.
patent: 2002/0115725 (2002-08-01), Epstein et al.
patent: 2007/0099999 (2007-05-01), Epstein et al.
patent: 2007/0100000 (2007-05-01), Epstein et al.
patent: 2007/0117869 (2007-05-01), Epstein et al.
patent: 1 743 641 (1707-01-01), None
patent: 2 122 617 (1984-01-01), None
patent: WO 97/17067 (1997-05-01), None
patent: WO 97/26871 (1997-07-01), None
patent: WO 99/16746 (1999-04-01), None
patent: WO 00/01379 (2000-01-01), None
patent: WO 00/32556 (2000-06-01), None
patent: WO 00/59479 (2000-10-01), None
patent: WO 01/09897 (2001-02-01), None
patent: WO 02/39998 (2002-05-01), None
patent: WO 02/053104 (2002-07-01), None
Chertkow, H., “Mild Cognitive Impairment,”Curr. Opin. in Neurol.15:401-407 (2002).
Clarke, A., “A New Formulation of Selegiline: Improved Bioavailability and Selectivity for MAO-B Inhibition,”J. Neural. Transm.110:1241-1255 (2003).
Gauthier, S., et al., “Mild Cognitive Impairment,”The Lancet367:1262-1270 (2006).
Grundman, M., et al., “Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials,”Arch. Neurol.61:59-66 (2004).
Halgren, E., et al., “Human Hippocampal Formation EEG Desynchronizes During Attentiveness and Movement,”Electroencephalography and Clinical Neurophysiology44:778-781 (1978).
Kwon, Y. S., et al., “Selegiline Potentiates the Effects of Egb 761 in Response to Ischemic Brain Injury,”Neurochemistry International45:157-170 (2004).
Lynch, G., et al., “The Nature and Causes of Hippocampal Long-term Potentiation,”Progress in Brain Research83:233-250 (1990).
Meeker, J.S. and Reynolds, P.C., “Postmortem Tissue Methamphetamine Concentrations Following Selegiline Administration,”J. of Analytical Toxicology14:330-331 (1990).
Mild Cognitive Impairment. Alzheimer's Society Information Sheet [online], Mar. 2005. Retrieved from the Internet <URL: http://www.alzheimers.org.uk>.
Mild Cognitive Impairment-Alzheimer's Disease Part XVI, [online] Nov. 2006 [retrieved on Jan. 24, 2007]. Retrieved from the Internet <URL:http://www.therubins.com>.
Nickel, B., et al., “Evaluation of Physical Dependence Liability ofl-deprenyl (Selegiline) in Animals,”Clinical Pharmacology&Theraptutics, 56(6):757-767 (1994).
Petersen, R.C., et al., “Current Concepts in Mild Cognitive Impairment,”Arch Neurol.58:1985-1992 (2001).
Semkova, I., et al., “Selegiline Enhances NGF Synbthesis and Protects Central Nervous System Neurons from Excitotoxic and Ischemic Damage,”European Journal of Pharmacology315:19-30 (1996).
Sivenius, J., et al., “Selegiline Treatment Facilitates Recovery After Stroke,”Neurorehabilitation and Neural Repair15:183-190 (2001).
Uchida, S., et al., “Cortical Oscillations in Human Medial Temporal Lobe During Wakefulness and All-night Sleep,”Brain Research891:7-19 (2001).
Yasar, S., et al., “Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(R)-(—)-Deprenyl],”The Journal of Pharmacology and Experimental Therapeutics 317(1):387-394 (2006).
Peterson, D. W., and Sparber, S. B., “Differential Actions of d- and l-amphetamine on the Metabolism of 3H-norepinephrine in Rat Brain,”Pharmacol. Biochem. Behav., 4(5): Abstract (1976).
Alafuzoff, I., et al., “Selegiline Treatment and the Extent of Degenerative Changes in Brain Tissue of Patients with Alzheimer's Disease,”Eur. J. Clin. Pharmacol., 55:815-819 (2000).
Alles, G. A., “Comparative Physiological Actions of the Optically Isomeric Phenisopropylamines,”University of California Publications in Pharmacology,129-150 (1939).
Angrist, B. M., et al., “Comparative Psychotomimetic Effects of Stereoisomers of Amphetamine,”Nature, 234:152-153 (1971).
Anisman, H. and Waller, T. G., “Effects of Methamphetamine and Shock Duration During Inescapable Shock Exposure on Subsequent Active and Passive Avoidance,”J. Comp.Physiol. Psychol., 77(1):143-151 (1971).
Arakawa, O., “Effects of Methamphetamine and Methylphenidate on Single and Paired Rat Open-Field Behaviors,”Physiol. Behav., 55(3):441-446 (1994).
Arnold, L. E., “Levoamphetamine vs Dextroamphetamine in Minimal Brain Dysfunction ,”Arch. Gen. Psychiatry., 33:292-301 (1976).
Arnold, L. E., “Levoamphetamine and Dextroamphetamine: Comparative Efficacy in the Hyperkinetic Syndrome,”Arch. Gen. Psychiat., 27:816-822 (1972).
Axelrod, J., “Amphetamine: Metabolism, Physiological Disposition and It's Effects on Catecholamine Storage,”Amphetamines and Related Compounds, 207-216 (1970).
Axelrod, J., “The Enzymatic Deamination of Amphetamine (Benzedrine),”Laboratory of Chemical Pharmacology, 753-763 (1954).
Balster, R. L., et al., “A Comparison ofd-Amphetamine,l-Amphetamine, and Methamphetamine Self-administration in Rhesus Monkeys,”Pharm. Biochem. Behav., 1:67-71(1973).
Barch, D. M., et al., “The Effects of D-Amphetamine on Language Function in Schizophrenia,”Society for Neuroscience Abstracts 23(l-2):p. 1952 (1997).
Bartus, R. T., “Drugs to Treat Age-Related Neurodegenerative Problems,”JAGS, 38(6):680-695 (1990).
Bartzokis, G., et al., “Selegiline Effects on Cocaine-Induced Changes in Medial Temporal Lobe Metabolism and Subjective Ratings of Euphoria,”Neuropsychopharmacology, 20(6): 582-590 (1999).
Bauer, R. and Evey, L., “Differential Effects of L-Amphetamine on Ontogeny of Active Avoidance, Intertitial Responses, and Locomotor Activity,”Psychopyharmacology75: 299-304 (1981).
Beckett, A. M., et al., “Metabolic Oxidation on Aliphatic Basic Nitrogen Atoms and Their α-carbon Atoms-Some Unifying Principles,”Letters to the Editor, J. Pharm. Pharmac.23:809-812 (1971).
Berlyne, D. E., “Arousal, Reward and Learning,”Ann. N. Y. Acad. Sci., 159(3):1059-1070 (1969).
Biel, J. H., “Structure-Activity Relationships of Amphetamine and Derivatives,”Amphetamines and Related Compounds, 3-19 (1970).
Biel, J. H. and Bopp. B. A., “Amphetamines: Structure-Activity Relationships,” in The Handbook of Psychopharmacology, vol. 11, stimulants, L. L. Iversen, S. D. Iverson. and S. H. Snyder. Eds.. Plenum Publishing Company, New York, 1978, pp. 1-39.
Birkmayer, W., “Long
Carpenter Randall L.
Epstein Mel H.
Wiig Kjesten A.
Cognition Pharmaceuticals LLC
Hamilton Brook Smith & Reynolds P.C.
Kwon Brian-Yong S
LandOfFree
Methods for treating cognitive impairment in humans with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cognitive impairment in humans with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cognitive impairment in humans with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4059979